- Home
- EQ vs PAVM Comparison
EQ vs PAVM Comparison
Compare EQ & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- PAVM
- Stock Information
- Founded
- EQ 2017
- PAVM 2014
- Country
- EQ United States
- PAVM United States
- Employees
- EQ N/A
- PAVM N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- EQ Health Care
- PAVM Health Care
- Exchange
- EQ Nasdaq
- PAVM Nasdaq
- Market Cap
- EQ 12.2M
- PAVM 12.0M
- IPO Year
- EQ 2018
- PAVM 2016
- Fundamental
- Price
- EQ $0.41
- PAVM $0.59
- Analyst Decision
- EQ Buy
- PAVM Strong Buy
- Analyst Count
- EQ 3
- PAVM 1
- Target Price
- EQ $3.00
- PAVM $19.00
- AVG Volume (30 Days)
- EQ 519.6K
- PAVM 117.0K
- Earning Date
- EQ 08-07-2025
- PAVM 08-11-2025
- Dividend Yield
- EQ N/A
- PAVM N/A
- EPS Growth
- EQ N/A
- PAVM N/A
- EPS
- EQ N/A
- PAVM 0.96
- Revenue
- EQ $30,406,000.00
- PAVM $1,993,000.00
- Revenue This Year
- EQ N/A
- PAVM N/A
- Revenue Next Year
- EQ N/A
- PAVM $455.63
- P/E Ratio
- EQ N/A
- PAVM $0.61
- Revenue Growth
- EQ N/A
- PAVM N/A
- 52 Week Low
- EQ $0.27
- PAVM $0.54
- 52 Week High
- EQ $1.50
- PAVM $1.90
- Technical
- Relative Strength Index (RSI)
- EQ 60.48
- PAVM 46.88
- Support Level
- EQ $0.29
- PAVM $0.57
- Resistance Level
- EQ $0.43
- PAVM $0.62
- Average True Range (ATR)
- EQ 0.06
- PAVM 0.03
- MACD
- EQ 0.01
- PAVM 0.00
- Stochastic Oscillator
- EQ 64.21
- PAVM 65.38
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.